Lp(a) meeting Prof. Marcovina emphasizes the importance of considering apo(a) size polymorphism when measuring Lp(a) levels in patients and discusses the Lp(a) Standardization Program.

Lp(a) meeting Existing clinical LDL-c assays cannot distinguish LDL-c from Lp(a)-c. Dr. Yeang discusses how Lp(a)-c is included in LDL-c measurements and what the clinical impact of measuring Lp(a)-c can be.

Lp(a) meeting Pia Kamstrup shares data of two general population studies that reveal the effects of elevated Lp(a) levels on CV events, and effects of Lp(a) risk genotypes, which are consistent with Lp(a) being a causal risk factor for CVD.

Lp(a) meeting Prof. Tsimikas discusses the phase 2 apo(a)-LRx trial that evaluated Lp(a) lowering with an antisense oligonucleotide and presents NHLBI recommendations on Lp(a) lowering.

Lp(a) meeting Small isoforms of Lp(a) are associated with high Lp(a) concentrations and increased CVD risk. The team of Kronenberg discovered a mutation in the Kringle-IV type 2 region of Lp(a), which has a modifying effect on Lp(a) levels and CVD risk.

Lp(a) meeting Elisa Waldmann shows prospective data on reduced CV event rates after regular Lp(a) apheresis in patients with high baseline Lp(a) levels and emphasizes the need of randomized controlled data.

Lp(a) meeting The prevalence of clinical FH was investigated in the Copenhagen General Population Study with adjustment for the cholesterol content in Lp(a). Prof. Nordestgaard shares possible ways to interpret these results.

Lp(a) meeting Zheng shows study results on the pathophysiological role of elevated Lp(a) and oxidized phospholipids levels in progression of aortic stenosis.

Slides as educational service to PACE members and meeting participants

Slides as educational service to PACE members and meeting participants

Slides as educational service to PACE members and meeting participants

Slides as educational service to PACE members and meeting participants